Benefit-risk assessment to support the FDA's decision on vaccines for SARS-CoV-2

被引：0
|
作者：
Yang, Hong [1 ]
机构：
[1] FDA, CBER, OBPV, Silver Spring, MD USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
243
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [41] SARS-CoV-2: vaccines in the pandemic era
    Dan-Dan Li
    Qi-Han Li
    Military Medical Research, 8
  • [42] SARS-CoV-2 vaccines: Lights and shadows
    Angeli, Fabio
    Spanevello, Antonio
    Reboldi, Gianpaolo
    Visca, Dina
    Verdecchia, Paolo
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2021, 88 : 1 - 8
  • [43] Cognitive, ethical, social and political aspects in risk assessment: regarding vaccines against SARS-CoV-2
    Novoa Jurado, Abel Jaime
    Maria Abellan, Jose
    GACETA SANITARIA, 2022, 36 (01) : 53 - 56
  • [44] Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines
    Arlegui, Hugo
    Bollaerts, Kaatje
    Salvo, Francesco
    Bauchau, Vincent
    Nachbaur, Gaelle
    Begaud, Bernard
    Praet, Nicolas
    DRUG SAFETY, 2020, 43 (11) : 1089 - 1104
  • [45] SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease
    Cosentino, Carlos
    Torres, Luis
    Velez, Miriam
    Nunez, Yesenia
    Sanchez, Danilo
    Armas, Cintia
    Alvarado, Marcela
    MOVEMENT DISORDERS, 2022, 37 (01) : 235 - 235
  • [46] Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
    Arlegui, Hugo
    Bollaerts, Kaatje
    Bauchau, Vincent
    Nachbaur, Gaelle
    Begaud, Bernard
    Praet, Nicolas
    DRUG SAFETY, 2020, 43 (11) : 1105 - 1120
  • [47] Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC)
    Hugo Arlegui
    Kaatje Bollaerts
    Vincent Bauchau
    Gaëlle Nachbaur
    Bernard Bégaud
    Nicolas Praet
    Drug Safety, 2020, 43 : 1105 - 1120
  • [48] RISK OF RELAPSE AFTER SARS-COV-2 VACCINATION IN PATIENTS WITH CHRONIC INFLAMMATORY NEUROPATHIES AND SAFETY AND TOLERABILITY OF THE SARS-COV-2 VACCINES
    Doneddu, Pietro
    Cocito, Dario
    Briani, Chiara
    Manganelli, Fiore
    Fabrizi, Gian Maria
    Mata, Sabrina
    Luigetti, Marco
    Inghilleri, Maurizio
    Carpo, Marinella
    Mazzeo, Anna
    Fazio, Raffaella
    Siciliano, Gabriele
    Filosto, Massimiliano
    Cosentino, Giuseppe
    Notturno, Francesca
    Sotgiu, Stefano
    Ruiu, Elena
    Antonini, Giovanni
    Giordano, Andrea
    Peci, Erdita
    Campagnolo, Marta
    Spina, Emanuele
    Cavallaro, Tiziana
    Sperti, Martina
    Romozzi, Marina
    Ceccanti, Marco
    Gentile, Luca
    Tronci, Stefano
    Schirinzi, Erika
    Piccinelli, Stefano Cotti
    Tamman, Giulia
    Carta, Alessandra
    Zarbo, Roberto
    Orazio, Eduardo Nobile
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S81 - S82
  • [49] Modeling the relative risk of SARS-CoV-2 infection to inform risk-cost-benefit analyses of activities during the SARS-CoV-2 pandemic
    McCarthy, John E.
    Dewitt, Barry D.
    Dumas, Bob A.
    McCarthy, Myles T.
    PLOS ONE, 2021, 16 (01):
  • [50] Real-world assessment of reinfection with SARS-CoV-2: Implications for vaccines
    Tseng, Kuang-Hung
    Chioua, Jeng-Yuan
    Wang, Shiow-Ing
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2025, 18 (01)
12345